# CBER

Type: organization

Source: GetYourBrief — https://getyourbrief.com/entity/cber-organization
Canonical HTML page: https://getyourbrief.com/entity/cber-organization

## Timeline

- **2026-03**: Final Departure — Official announcement of Marks leaving the agency for the second time.
- **2026-02-24**: Formal Proposal — FDA formally proposes the new customized drug approval system for ultra-rare diseases.
- **2025-11-10**: BGTC Pilot Completion — The Bespoke Gene Therapy Consortium completes its first round of pilot manufacturing runs.
- **2025**: Initial Friction — Reports surface of Marks considering resignation amid administrative policy shifts.
- **2024-05-15**: Draft Guidance Issued — FDA releases initial thoughts on 'n-of-1' therapy development and manufacturing.
- **2022-12-29**: PREVENT Act Passed — Congress directs FDA to establish a framework for platform technology designations.
- **2020**: Operation Warp Speed — Plays a central role in the emergency use authorizations for COVID-19 vaccines.
- **2016**: Appointed Director — Promoted to Director of CBER, overseeing the 'Gold Standard' of vaccine review.
- **2012**: Joins FDA — Dr. Peter Marks joins the FDA as Deputy Director of CBER.

## Recent coverage (3 stories, network-wide)

### FDA Vaccine Chief Departs Amid Regulatory Turmoil and Political Pressure
2026-03-07 01:54:04 · Sector: bio · Sentiment: Negative · Impact: 6/10 · Sources: 6

The head of the FDA’s vaccine division is stepping down for the second time, marking a significant leadership vacuum at a critical juncture for the agency. This departure follows a period of intense scrutiny and reported friction between the regulatory body and the Trump administration over vaccine authorization protocols.
Full story: https://getbiobrief.com/story/fda-vaccine-chief-resignation-trump-administration

### FDA Vaccine Chief Departs Amid Regulatory Overhaul and Political Pressure
2026-03-07 01:51:00 · Sector: health · Sentiment: Negative · Impact: 6/10 · Sources: 6

Dr. Peter Marks, the long-serving head of the FDA’s vaccine division, is stepping down for the second time as the Trump administration intensifies its 'Make America Healthy Again' initiatives. His exit marks a critical turning point for the Center for Biologics Evaluation and Research and signals a potential shift in the agency's rigorous approval standards.
Full story: https://gethealthbrief.com/story/fda-vaccine-chief-departure-trump-administration

### FDA Unveils 'Platform' Pathway to Accelerate Bespoke Rare Disease Therapies
2026-02-24 03:18:36 · Sector: bio · Sentiment: Positive · Impact: 8/10 · Sources: 2

The FDA has proposed a landmark regulatory framework to streamline the approval of customized, 'n-of-1' therapies for ultra-rare diseases. By shifting focus from individual products to validated manufacturing platforms, the agency aims to drastically reduce the time and cost of bringing genetic treatments to patients with unique mutations.
Full story: https://getbiobrief.com/story/fda-proposes-customized-drug-approval-system

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.